Across TCGA pan-cancer cohorts, ANP32D mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of ANP32D’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where ANP32D mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ANP32D is over-expressed in tumor.
LUAD are the cancer types where ANP32D tumor–normal differential expression is most reproducible.